Navigation Links
Takeda Receives FDA Approval for Three New Type 2 Diabetes Therapies, NESINA (alogliptin) and Fixed-Dose Combinations OSENI (alogliptin and pioglitazone) and KAZANO (alogliptin and metformin HCl)
Date:1/25/2013

DEERFIELD, Ill. and OSAKA, Japan, Jan. 25, 2013 /PRNewswire/ -- Takeda Pharmaceutical Company Limited (Takeda) and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc. today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved NESINA (alogliptin) and the fixed-dose combination (FDC) therapies OSENI (alogliptin and pioglitazone) and KAZANO (alogliptin and metformin HCl) for the treatment of type 2 diabetes in adults as adjuncts to diet and exercise.

"Takeda is pleased with the FDA approval of NESINA, OSENI and KAZANO for the treatment of type 2 diabetes, a therapeutic category in which we have more than twenty years of clinical and patient experience," said Douglas Cole , president, Takeda Pharmaceuticals U.S.A., Inc. "Millions of people are affected by diabetes and, as a leader in the diabetes arena, Takeda is dedicated to working to advance patient care and helping to meet the needs of this growing patient population."

NESINA is a dipeptidyl peptidase-4 inhibitor (DPP-4i) that is designed to slow the inactivation of incretin hormones GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic peptide). OSENI, which combines alogliptin with pioglitazone, is the first product in the U.S. to include both a DPP-4i and a thiazolidinedione (TZD) in a single tablet. KAZANO combines alogliptin with metformin HCl, a widely used anti-diabetes medication, in a single tablet.

The most common adverse events (greater than or equal to 4%) reported with NESINA include nasopharyngitis, headache and upper respiratory tract infection. With regard to OSENI, common adverse events (greater than or equal to 4%) reported include nasopharyngitis, back pain and upper respiratory tract infection. Common adverse events (greater than or equal to 4%) re
'/>"/>

SOURCE Takeda Pharmaceutical Company Limited
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. FDA Accepts Takeda and Lundbecks Submission of the New Drug Application for Vortioxetine for the Treatment of Major Depressive Disorder
2. Takedas Deerfield Campus Ranked Among Chicagos Top 100 Workplaces in 2012
3. Takeda Completes its Russian Pharmaceutical Manufacturing Facility
4. Takeda Resubmits New Drug Applications to the United States Food and Drug Administration for Alogliptin and the Fixed-Dose Combination Alogliptin and Pioglitazone
5. Zacks Bull and Bear of the Day Highlights: Discover Financial Services, POSCO, AstraZeneca, Bayer and Takeda Pharmaceutical
6. Takeda to Acquire Multilab, Enhancing its Business Infrastructure in Brazil
7. IntelliCell BioSciences Receives Notice of Allowance for its US Patent for "Ultrasonic Cavitation of Adipose Tissue to Produce Stromal Vascular Fraction Regenerative Cells"
8. Zimmer Receives FDA Clearance for Revolutionary New Surgical Guidance Technology
9. American Capital Receives $60 Million From The Sale Of Lifoam Holdings And Generates An 11% Return On Its Investment
10. PrimeMail, Prime Therapeutics mail-service pharmacy, receives URAC Reaccreditation
11. Brolex C SAFE cesarean section safety device receives top scores, rated a MUST HAVE medical device for performing c/sections.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2015)... Hospira, Inc. (NYSE: ... Biosimilar-Behandlungen, sprach heute auf der jährlichen Konferenz der ... London über die Bedeutung ... Biosimilars für Patienten. Das Unternehmen kündigte ... dem Titel „Why extrapolation is paramount to ...
(Date:4/25/2015)... 2015  With the introduction of Elekta,s new Leksell ... are now available for more patients with a wider ... stereotactic radiosurgery system for the brain, integrates advanced motion ... versatility of Gamma Knife radiosurgery. Elekta unveiled Leksell Gamma ... Forum in Barcelona . ...
(Date:4/24/2015)... Hampshire , und BARCELONA ... -- (Stand Nr. 4410) iCAD, Inc. (Nasdaq: ... von moderner Bildanalyse, Lösungen für Behandlungsabläufe und ... Krebserkrankungen, hat heute die sofortige Verfügbarkeit des ... Electronic Brachytherapy (eBx ® ) System ® ...
Breaking Medicine Technology:Führungskräfte von Hospira präsentieren auf bedeutendem europäischen Biosimilars-Forum - Ankündigung eines White Papers über Extrapolation 2Führungskräfte von Hospira präsentieren auf bedeutendem europäischen Biosimilars-Forum - Ankündigung eines White Papers über Extrapolation 3Führungskräfte von Hospira präsentieren auf bedeutendem europäischen Biosimilars-Forum - Ankündigung eines White Papers über Extrapolation 4Führungskräfte von Hospira präsentieren auf bedeutendem europäischen Biosimilars-Forum - Ankündigung eines White Papers über Extrapolation 5Führungskräfte von Hospira präsentieren auf bedeutendem europäischen Biosimilars-Forum - Ankündigung eines White Papers über Extrapolation 6Führungskräfte von Hospira präsentieren auf bedeutendem europäischen Biosimilars-Forum - Ankündigung eines White Papers über Extrapolation 7Führungskräfte von Hospira präsentieren auf bedeutendem europäischen Biosimilars-Forum - Ankündigung eines White Papers über Extrapolation 8New Leksell Gamma Knife to benefit more patients with brain disease 2New Leksell Gamma Knife to benefit more patients with brain disease 3Erste Klinik in Spanien setzt das Xoft Electronic Brachytherapy System für die Behandlung von Brustkrebs im Frühstadium, nicht-melanozytärem Hautkrebs und gynäkologischen Krebserkrankungen ein 2Erste Klinik in Spanien setzt das Xoft Electronic Brachytherapy System für die Behandlung von Brustkrebs im Frühstadium, nicht-melanozytärem Hautkrebs und gynäkologischen Krebserkrankungen ein 3Erste Klinik in Spanien setzt das Xoft Electronic Brachytherapy System für die Behandlung von Brustkrebs im Frühstadium, nicht-melanozytärem Hautkrebs und gynäkologischen Krebserkrankungen ein 4Erste Klinik in Spanien setzt das Xoft Electronic Brachytherapy System für die Behandlung von Brustkrebs im Frühstadium, nicht-melanozytärem Hautkrebs und gynäkologischen Krebserkrankungen ein 5Erste Klinik in Spanien setzt das Xoft Electronic Brachytherapy System für die Behandlung von Brustkrebs im Frühstadium, nicht-melanozytärem Hautkrebs und gynäkologischen Krebserkrankungen ein 6
... CITY, Calif., Jan. 6, 2012  myoscience, Inc. of Redwood ... Robert E. Grant as Chairman of the Board of ... Chief Executive Officer and President of Bausch & Lomb ... Allergan.  Mr. Grant has been a board member for ...
... USHIFU, LLC (US HIFU), a world leader in minimally ... Klein as the company,s new chief executive officer and ... more than 30 years of experience in oncology and ... as president of the radiation oncology division of Roper ...
Cached Medicine Technology:myoscience Announces Robert Grant as Chairman of the Board 2US HIFU Names New Chief Executive Officer 2US HIFU Names New Chief Executive Officer 3
(Date:4/25/2015)... Washington, DC (PRWEB) April 26, 2015 ... for Seniors (ACE.S) , a national endeavor to prepare ... older adults, is a great success, according to a ... of the program's original funding partners. , The ... College of Philadelphia (CCP), under the direction of Elaine ...
(Date:4/25/2015)... 2015 Diversified Communications has announced ... event. The Integrative Healthcare Symposium Canada, as it’s ... at the Sheraton Parkway Toronto North in Ontario. ... of the most anticipated events of the year ... program. The event aims to gather multi-disciplined practitioners ...
(Date:4/25/2015)... 26, 2015 Avid Collector Andrew Hawley ... Rolling Stones Greensboro Coliseum concert posters. The concert was ... the Stone's Second American Tour. , According to ... out of Baltimore, Maryland. This poster blank was used ... southern cites. Globe uses garish lettering and colors on ...
(Date:4/25/2015)... D.C. (PRWEB) April 25, 2015 In ... worldwide will join The Million Nets Pledge, a two-year ... campaign to protect refugee families with one million bednets ... their increased work with UN partners to protect children, ... from malaria. , “There has been a large ...
(Date:4/25/2015)... The Hon. Ellen Tauscher, Independent Chair of the ... following the deadly earthquake in Nepal: , "Today a ... deaths of more than 1,000 people. The aftershocks ... India and other parts of South Asia. I ... of Nepal and the families of the victims. ...
Breaking Medicine News(10 mins):Health News:Hartford Foundation Report Details Success of NLN's Advancing Care Excellence for Seniors (ACE.S) Program 2Health News:Hartford Foundation Report Details Success of NLN's Advancing Care Excellence for Seniors (ACE.S) Program 3Health News:Integrative Healthcare Event launching in Canada 2Health News:Supporters Worldwide Join The Million Nets Pledge on World Malaria Day 2Health News:Supporters Worldwide Join The Million Nets Pledge on World Malaria Day 3Health News:Supporters Worldwide Join The Million Nets Pledge on World Malaria Day 4
... be as effective as a second medication for as ... not been cured by a single antidepressant medication. ... recently published in the Journal of Clinical Psychiatry, found ... can work as well as administering a second antidepressant ...
... , TUESDAY, Aug. 23 (HealthDay News) -- Accidental ... cancer nurses in the United States, a new study ... state who work in outpatient chemotherapy infusion centers and ... eyes had been exposed to the drugs. In ...
... -- Researchers say boys are becoming physically mature earlier ... reaching sexual maturity about 2.5 months earlier every decade ... reason for earlier maturity for boys, as with girls, ... more favorable for it," demographer Joshua Goldstein, director of ...
... By Maureen Salamon HealthDay Reporter , TUESDAY, ... research investigating injectable drugs to treat psoriasis -- an ... the medications are not linked to higher heart risks. ... complete information from drug makers impeded their ability to ...
... than 1 million patients in North America, results from ... as bacteria, in people genetically predisposed to the disorder. ... colon, is one such condition. The aberrant immune ... small signaling proteins secreted by various cells, including ...
... TUESDAY, Aug. 23 (HealthDay News) -- A test that detects ... likely to raise the risk of invasive cervical cancer, when ... many women than the Pap test alone, a new study ... the HPV test alone appears to be enough, said study ...
Cached Medicine News:Health News:Exercise can substitute effectively as second 'medication' for people with depression 2Health News:Nurses at Risk for Accidental Exposure to Chemo Drugs: Study 2Health News:Boys Mature Sexually Earlier Than Ever Before: Study 2Health News:Injectable Psoriasis Drugs May Not Hike Heart Risks: Study 2Health News:Injectable Psoriasis Drugs May Not Hike Heart Risks: Study 3Health News:Novel cytokine protects mice from colitis 2Health News:HPV Test Might Be Better Predictor of Cervical Cancer Than Pap Smear 2Health News:HPV Test Might Be Better Predictor of Cervical Cancer Than Pap Smear 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: